This research study will evaluate the safety and efficacy of a study drug called TGR-1202 in combination with another study drug called ublituximab compared to TGR-1202 alone as a possible treatment for Diffuse Large B-cell Lymphoma (DLBCL) that has come
Ages Eligible for Study: 18 Years and older (Adult, Senior)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Histologically confirmed diagnosis of: B-cell NHL with histological subtype limited to the following:
a. Follicular Lymphoma (FL) of Grade 1, 2, or 3a;
b. Marginal Zone Lymphoma (MZL) (splenic, nodal, or extranodal); or
c. Mantle Cell Lymphoma (MCL) – with documentation of either overexpression of cyclin D1 or t(11;14).
> Any major surgery, chemotherapy or immunotherapy within the last 21 days
> Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
> Autologous hematologic stem cell transplant within 3 months of study entry.
> Prior Allogeneic hematologic stem cell transplant is excluded
> Prior therapy with a PI3K delta inhibitor
21st Century Oncology will be moving to their new home as part of the global GenesisCare network. The 21st Century Oncology website will no longer exist after November 2020.
There will be no disruption in your care team, location, or contacts. There will simply be a new website, new look and feel, and patients will benefit from the latest treatment technology and evidence-based cancer care. We look forward to serving you as part of the GenesisCare team.